Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.
Katherine G YoungEram Haider McInnesRobert J MasseyAnna R KahkoskaScott J PillaSridharan RaghavanMaggie A StanislawskiDeirdre K TobiasAndrew P McGovernAdem Y DawedAngus G JonesEwan R PearsonRaphael Sonabendnull nullPublished in: Communications medicine (2023)
Current evidence on treatment effect heterogeneity for SGLT2-inhibitor and GLP1-receptor agonist therapies is limited, likely reflecting the methodological limitations of published studies. Robust and appropriately powered studies are required to understand type 2 diabetes treatment effect heterogeneity and evaluate the potential for precision medicine to inform future clinical care.